Obesity pillarsJul 13, 2026

Changes in food cravings, diet quality, body weight, and eating habits during treatment with GLP-1 receptor medicines

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 14, 2026

Abstract

Changes in diet quality and body composition were evaluated over 24 weeks of GLP-1 RA OMM therapy.

Improvements in diet quality may occur during GLP-1 RA OMM therapy.
Food cravings could change as a result of the therapy.
Dietary intake is associated with the effects of GLP-1 RA OMM therapy.
Body composition changes may be observed during the 24-week treatment period.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

A.K.F. reports work on advisory boards for Currax Pharmaceuticals LLC, Eli Lilly, Ms.Medicine, Novo Nordisk, Rhythm Pharmaceuticals, SideKick Health, Seca, and VIVUS.

PubMed

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

2 days ago7 studies

The brain region that explains why blocking and activating the same receptor both cause weight loss

1 week ago7 studies

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

2 weeks ago7 studies

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

3 weeks ago7 studies

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

4 weeks ago7 studies

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

5 weeks ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

6 weeks ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

7 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

8 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief